Gainor et al. demonstrated that NSCLC patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation exhibit a lower response rate to ICB treatment (57). Here, ALK is linked to non-small cell lung carcinoma.